Jan 24 2023

Halberd Agrees to Animal Testing at Mississippi State University

By |2023-01-23T17:04:28-05:00January 24th, 2023|Investor News, Medical, News, Press Releases|0 Comments

College of Veterinary Medicine to conduct testing Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will ...

Dec 5 2022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

By |2022-12-04T16:15:09-05:00December 5th, 2022|Featured, Investor News, Medical, News|0 Comments

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully ...

Nov 30 2022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

By |2022-11-30T19:22:58-05:00November 30th, 2022|Featured, Investor News, Medical, News|0 Comments

UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.”  The article has been peer ...

Nov 17 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

By |2022-11-17T05:15:05-05:00November 17th, 2022|Featured, Investor News, Medical, News|0 Comments

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in ...

Oct 18 2022

Halberd Laser Therapy Eliminates Over 90% of Multiple Antibiotic Resistant Bacteria in Minutes

By |2022-10-17T20:12:29-04:00October 18th, 2022|Investor News, Medical, News, Press Releases|1 Comment

Could be Instrumental in Curing Sepsis, Meningitis Among Other Life-Threatening Diseases Jackson Center, PA, October 18, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has successfully eliminated various antibiotic resistant bacteria from buffer solution , in-vitro, through the use of a single designer monoclonal antibody conjoined to a metallic nanoparticle which attaches to the bacteria.  The combined ...

Aug 23 2022

Halberd Demonstrates Precise Control of Key Cancer Related T-Cell Protein

By |2022-08-22T20:05:56-04:00August 23rd, 2022|Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, August 23, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated the ability to precisely control the level of PD-1 in human blood serum in laboratory in-vitro testing.  PD-1 (programmed cell death–1) is a T-Cell protein which can be used by tumor cells to fool the body’s immune system into allowing the ...

Apr 27 2022

Dr. Gregg Sturrus’ TEDx Talk Features Halberd’s Extracorporeal Treatment of Neurodegenerative Diseases

By |2022-04-27T16:28:20-04:00April 27th, 2022|Medical, News, Videos|0 Comments

Jackson Center, PA, April 27, 2022 – A key member of Halberd Corporation’s (OTC PINK:HALB) Research Team, Dr. W. Gregg Sturrus, recently gave a TEDx Talk® on Halberd’s patented and patent-pending extracorporeal elimination of neurodegenerative disease proteins and cytokines using lasers and metallic nanoparticles. Dr. Sturrus, in his talk, provided a brief ...

Apr 18 2022

Halberd Eliminates E. coli in 20 Minutes vs. 7-10 Days with Conventional Antibiotics

By |2022-04-17T19:16:30-04:00April 18th, 2022|Featured, Investor News, Medical, Press Releases|0 Comments

Jackson Center, PA, April 18, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the efficacy of its patented extracorporeal methodology for treatment and eradication of disease states.  The latest success was again extracorporeal elimination of E. coli bacteria from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro, in under 20 minutes.  This ...

Apr 4 2022

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

By |2022-04-05T20:32:09-04:00April 4th, 2022|Investor News, Medical, News, Press Releases|Comments Off on Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, PA, April 4, 2022 – Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro.  Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic ...

Mar 1 2022

Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant

By |2022-03-01T10:07:25-05:00March 1st, 2022|Featured, Investor News, Medical, News|0 Comments

Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen.  The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies.  The results are shown ...

Go to Top